Connect with us

Technology

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

Published

on

NANJING, China, Sept. 2, 2024 /PRNewswire/ — On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase inhibitor TGRX-326, a clinical-stage anti-tumor candidate.

According to the terms of the agreement, Simcere Zaiming will acquire exclusive commercial rights to TGRX-326 in Mainland China. These rights encompass but are not limited to marketing promotion, strategy formulation and adjustment, and the right to obtain relevant benefits from TGRX-326. TargetRx will receive an initial payment exceeding $20 million. Additionally, TargetRx will compensate Simcere Zaiming for promotional services.

TGRX-326 is a third-generation anaplastic lymphoma kinase (ALK) inhibitor independently developed by TargetRx. It is a potent and highly selective small molecule inhibitor that targets ALK and c-ROS proto-oncogene 1 (ROS1) receptor tyrosine kinases (RTKs). This inhibitor holds significant therapeutic potential for ALK/ROS1 fusion gene-positive non-small cell lung cancer (NSCLC) patients, especially those with multiple ALK-resistant mutations, including G1202R.

In preclinical studies and a Phase 1 clinical trial, TGRX-326 demonstrated robust anti-tumor activity and a favorable safety profile. Moreover, the molecule effectively crosses the blood-brain barrier, exhibiting exceptional efficacy in NSCLC patients with brain metastases.

Dr. Renhong Tang, Chairman of Simcere Zaiming, said, “We are pleased to collaborate with TargetRx on novel dual-targeted therapy for lung cancer, a major malignancy that Simcere Zaiming strategically focuses on. This partnership will further enhance our innovative product portfolio. ALK/ROS1 fusion is a critical genetic mutation in non-small cell lung cancer. The advancement of targeted therapies has significantly improved survival rates for these patients. However, there remains a substantial need for new treatments with better efficacy and the ability to overcome drug resistance. We look forward to working closely with TargetRx to provide Chinese lung cancer patients with more effective treatment options as soon as possible.”

Dr. Yihan Wang, Chairman of TargetRx, said, “TGRX-326 is a potentially best-in-class novel anti-tumor molecule independently developed by TargetRx. It is a third-generation ALK inhibitor in late-stage clinical development which may bring a better option for patients. We believe that with the support of Simcere Zaiming, we will be able to bring this product quickly to the market. TargetRx aims to continuously deliver innovative therapies that will transform the lives of cancer patients.”

About Simcere Zaiming

Simcere Zaiming, an oncology-centric biopharmaceutical subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096), was established in 2023. The company is dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several products in China, including COSELA®, Endostar®, Enweida®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners in cancer therapeutics. 

About TargetRx

TargetRx is a clinical stage, high-tech pharmaceutical R&D company focused on developing next-generation targeted therapies for cancer patients, particularly those who are resistant or refractory to current treatments. TargetRx has developed a series of cutting-edge and efficient small molecule drug discovery platforms, which combine innovative research and development capabilities for drug design, screening, evaluation and optimization. Since its establishment, TargetRx has been granted over 170 patents from authorities in China, the US, Europe, Japan and other regions. Several potential best-in-class compounds are at different stages of multi-national clinical trials.

View original content:https://www.prnewswire.com/news-releases/simcere-zaiming-collaborates-with-targetrx-to-introduce-a-third-generation-alk-inhibitor-302235944.html

SOURCE Simcere Pharmaceutical Group Limited

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

AMTD’s TGE Reports Full Year Results with 27.7% Increase in Revenue, with 25.5% Increase in Total Assets and 9.1% Increase in Net Assets

Published

on

By

PARIS and LONDON and NEW YORK, April 29, 2026 /PRNewswire/ — The Generation Essentials Group (“TGE” or the “Company”) (NYSE: TGE, LSE; TGE), a NYSE and LSE dual-listed company and a subsidiary of AMTD Group Inc., today announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission, with summary highlights below:

Total Revenue increased by 27.7% from US$77.0 million to US$98.3 millionTotal non-GAAP Net Income increased by 3.2% from US$44.7 million to US$46.2 million Total Assets amounted to US$1,464.1 million (US$30.2/share)Net asset value amounted to US$839.1 million (US$17.3/share)

The annual report is available on the Company’s investor relations website at  http://thegenerationalessentials.com. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations Office at ir@tge.media.

About The Generation Essentials Group

The Generation Essentials Group (NYSE: TGE; LSE: TGE), jointly established by AMTD Group, AMTD IDEA Group (NYSE: AMTD; SGX: HKB) and AMTD Digital Inc. (NYSE: HKD), is headquartered in France and focuses on global strategies and developments in multi-media, entertainment, and cultural affairs worldwide as well as hospitality and VIP services. TGE comprises L’Officiel, The Art Newspaper, movie and entertainment projects. Collectively, TGE is a diversified portfolio of media and entertainment businesses, and a global portfolio of premium properties. Also, TGE is a special purpose acquisition company (SPAC) sponsor manager, with its first SPAC successfully raised and priced on December 18, 2025.

For The Generation Essentials Group:
IR Office
The Generation Essentials Group
EMAIL: ir@tge.media

View original content:https://www.prnewswire.com/news-releases/amtds-tge-reports-full-year-results-with-27-7-increase-in-revenue-with-25-5-increase-in-total-assets-and-9-1-increase-in-net-assets-302757926.html

SOURCE The Generation Essentials Group

Continue Reading

Technology

Potatoes USA Awarded Patent for AI-Driven Social Media Monitoring and Responding

Published

on

By

DENVER, April 29, 2026 /PRNewswire/ — Potatoes USA, the national promotion board for U.S. potato growers and importers, has been awarded a patent (US 12,591,622 B2) for a method for monitoring and responding to social media content.

The innovative technology automates social media management, featuring AI-driven monitoring, content identification, and natural language response generation on a knowledge basis. The system may include a human-in-the-loop interface that allows for the review, editing, and approval of generated content prior to publication.

Potatoes USA uses the technology to monitor for misinformation about potato nutrition so they can respond with the correct information, educating consumers on the nutritional benefits of potatoes. Additionally, the organization uses the technology to participate in positive conversations about potatoes, joining in the vast amount of potato love on social media.

“For any company or brand trying to share information and raise awareness, it’s vital to be part of relevant conversations happening on social media. This technology allows us to participate in and, more importantly, help shape those conversations,” said Blair Richardson, CEO of Potatoes USA. “A huge number of people talk about potatoes on social media every day. The vast majority of what we see is very positive, but we also find negative and incorrect posts and comments about potatoes. Even though it’s a smaller percentage of what’s being said, it’s a key piece of our communications strategy to correct the misinformation that’s out there, debunk longstanding myths about potatoes, and educate the public on the true nutritional benefits of potatoes.”

The patented technology allows Potatoes USA to establish itself as a go-to resource on social media for potato nutrition facts, recipe inspiration, and general potato love.

About Potatoes USA
As representatives of U.S. potato growers and importers, Potatoes USA’s mission is to strengthen the demand for potatoes through marketing and research. By launching impactful marketing campaigns; coordinating regional, national, and international market and production research; and establishing new trade markets, Potatoes USA promotes the benefits of potatoes to audiences across the globe, including consumers, foodservice operators, retailers, and health professionals. For more information on America’s Favorite Vegetable, please visit PotatoGoodness.com and PotatoesUSA.com.

Media Contact
Erin Bracken
media@hillenby.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/potatoes-usa-awarded-patent-for-ai-driven-social-media-monitoring-and-responding-302757930.html

SOURCE Potatoes USA

Continue Reading

Technology

TERAGO to Hold Investor Conference Call to Discuss First Quarter 2026 Financial Results

Published

on

By

TORONTO, April 29, 2026 /CNW/ – TERAGO Inc. (“TERAGO” or the “Company”) (TSX: TGO) www.terago.ca, Canada’s 91% mmWave spectrum holder and a leading provider of Managed Fixed Wireless Internet, 5G Private Wireless Networks and SD-WAN secure solutions today announced that it will be hosting a conference call on Wednesday, May 13, 2026, at 10:00 a.m. ET to discuss its financial results for the first quarter of 2026. The complete financial results are expected to be released after market close on Tuesday, May 12, 2026.

The Company’s results along with a presentation in connection with the conference call will be made available on the Company’s website at https://terago.ca/company/investor-relations/.

To access the conference call, please dial 888-506-0062 or 973-528-0011 and use conference ID 135943 if applicable. Please call the conference telephone number 15 minutes prior to the start time so that you are in the queue for an operator to assist in registering and patching you through.

A replay of the conference call will be available through Wednesday, May 27, 2026 and can be accessed by dialing 877-481-4010 or 919-882-2331 and using passcode 53968.

About TERAGO
TERAGO provides managed network and security services to businesses across Canada ensuring highly secure, reliable and redundant connectivity including private 5G wireless networks, fixed wireless access, fiber and cable wireline network connectivity. As Canada’s biggest mmWave spectrum holders, the Company possesses exclusive spectrum licenses in the 24 GHz and 38 GHz spectrum bands, which it utilizes to provide secure, dedicated SLA guaranteed enterprise grade performance that is technology diverse from buried cables ensuring high availability connectivity services. TERAGO serves Canadian and Global businesses operating in major markets across Canada, including Toronto, Montreal, Calgary, Edmonton, Vancouver, Ottawa and Winnipeg, and has been providing wireless services since 1999. For more information about TERAGO and its suite of wireless internet and SDWAN solutions, please visit www.terago.ca.

SOURCE TeraGo Inc.

Continue Reading

Trending